Halozyme announces proposed $1.05B convertible notes due 2033
Halozyme Therapeutics said it intends to offer $1.05 billion of convertible senior notes due 2033, subject to market conditions and other factors.
Story updates
08:31:13 PM UTC
SquawkNews
Halozyme intends to offer $1.05B of convertible senior notes due 2033, with an option for $150M more, to fund capped calls, repurchase parts of its 2027/2028 notes, and for general purposes.Material DetailsContext by AI AnalystThis is a balance-sheet move typical of mid-cycle refinancings, shifting…
05B of convertible senior notes due 2033, with an option for $150M more. The company said proceeds would be used to fund capped calls, repurchase parts of its 2027 and 2028 notes, and for general purposes.